David Arkin, MD
Endocrinology, Diabetes & Metabolism · Lawrenceville, GANPI 1891865937
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.6% of the total across 711 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations.
Across 711 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Novo Nordisk$2K
- Amgen$2K
- Sanofi-aventis U.S. LLC$1K
- Lilly USA, LLC$752
- Insulet Corporation$715
- plus $7K from 54 others
What the payments were for
- Speaking & faculty fees$4503%
- Food & beverage$14,46396%
- Education$1511%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$934
- SOLIQUA 100/33$450
- iLet Bionic Pancreas$430
- DEXCOM G6 TRANSMITTER$360
- Omnipod$276
- EVENITY$261
- TEPEZZA$252
- t:slim X2 Insulin Pump with Control-IQ$225
- FreeStyle Libre$147
- t-slim insulin pump$145
- REZDIFFRA$140
- Ozempic$116
- Veozah$108
- FARXIGA$104
How this compares
$15,124 in reported general payments places this provider in the 85th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 277 | $510,411 |
| MounjaroTirzepatide | 269 | $385,787 |
| JardianceEmpagliflozin | 186 | $255,375 |
| TrulicityDulaglutide | 115 | $159,370 |
| FarxigaDapagliflozin Propanediol | 101 | $133,976 |
| JanuviaSitagliptin Phosphate | 80 | $114,628 |
| ProliaDenosumab | 55 | $94,677 |
| Tresiba Flextouch U-200Insulin Degludec | 49 | $84,639 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $61,175 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 65 | $60,407 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 51 | $56,972 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 21 | $40,575 |
| Humalog Kwikpen U-100Insulin Lispro | 61 | $39,471 |
| Tresiba Flextouch U-100Insulin Degludec | 47 | $38,933 |
| SynthroidLevothyroxine Sodium | 334 | $34,212 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $752 | $545,157384 claims |
| Novo NordiskOzempic, Rybelsus | $1,775 | $529,155288 claims |
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr | $305 | $289,146218 claims |
| MerckJanuvia, Janumet Xr, Janumet | $51 | $189,295145 claims |
| AstraZenecaFarxiga | $596 | $133,976101 claims |
| AmgenProlia | $1,516 | $94,67755 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $1,259 | $45,26452 claims |
| AbbVieSynthroid, Armour Thyroid | $292 | $37,622374 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $174 | $12,8581,254 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Lawrenceville
- Adeniyi OdugbesanLawrenceville$636K
- David ShoreLawrenceville$83K
- Aparna MahakalaLawrenceville$12K
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Miguel MunozMarietta$476K
- Jason BernerJasper$457K
- Dawn Smiley-ByrdTaylorsville$385K
- Barry JohnsMacon$335K
- Jonathan OwnbyAtlanta$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.